As Tuesday’s trading session is coming to a close, the broad markets have turned positive. With the Dow and S&P 500 having been negative for a majority of the day, most of the stories we have been seeing have been on the pessimistic side like 6 Serious Earnings Disappointments That Smacked Shareholders. However as the markets have turned positive, 24/7 Wall St. has picked out a few stocks that have powered through the day as the result of stellar earnings reports.
We tracked four big stock movers to the upside after earnings or guidance. We are also seeing huge volume spikes in these names. Included with each summary is how great each report looked, or what other opportunities were seen, as well as trading color on each company.
Atwood Oceanics, Inc. (NYSE: ATW) reported better than expected results for its fiscal fourth quarter, and saw its shares skyrocket. The company had $2.32 in earnings per share (EPS) on $363.2 million compared to consensus estimates from Thomson Reuters that called for $1.93 in EPS on $346.2 million. Considering the weakness that we have seen in oil over the past year, this earnings beat begs the question: Is this offshore drilling contractor signaling a turnaround?
Shares of Atwood were last trading up 11.5% at $18.91, with a consensus analyst price target of $19.74 and a 52-week trading range of $14.15 to $38.84.
As one of the big players in the cloud computing space, Rackspace Hosting, Inc. (NYSE: RAX) has made a name for itself in the market, but its performance on the year has been less than favorable with the stock down 42% year to date (Monday’s close). However these earnings could be signaling a turnaround. In its third quarter, the company had $0.26 in EPS on $508.9 million in revenue compared to consensus estimates that called for $0.20 in EPS on $503 million in revenue. Rackspace shares were last seen up 15.3% at $31.24.
Rackspace’s stock has a consensus analyst price target of $39.53 and a 52-week trading range of $23.65 to $56.20.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that it had $0.26 in earnings per share and $42.9 million in revenue. Zadaxin is the primary drug in the SciClone portfolio, not to mention it made up about 91% of the company’s sales; it is used in the treatment of hepatitis B. Sales of Zadaxin jumped an incredible 22% to roughly $39 million in this quarter, considering other Biotech giants like Gilead have recently scaled their hepatitis (C) treatments with incredible success, the outlook is very bright for SciClone. Currently Zadaxin is not available in the U.S., so there is room for expansion.
The company does most of its sales in China. Shares of SciClone were up nearly 24% at $9.90, with a consensus analyst price target of $10.00 and a 52-week trading range of $6.47 to $11.71.
Another player from the oil-and-gas field makes the list, McDermott International Inc. (NYSE: MDR) had an amazing third quarter driven by new contracts that fostered solid execution. The company had $0.09 in EPS on $806 million in revenues compared to consensus estimates of a net loss of $0.05 per share on $780 million in revenue.
McDermott shares were up 11.4% at $5.85, with a consensus analyst price target of $5.84 and a 52-week trading range of $2.10 to $5.98.